Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ablation + Lenvatinib + Sintilimab for Recurrent HCC
NCT05803928Phase 1Recruiting
- Sponsor
- Hua Medicine
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenvatinib and sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Hua Medicine. Primary endpoint: Recurrence-free Survival at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
lenvatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05803928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803928.